Skip to Main Content

Gastroenterology: Morning and Noon Conference

Morning and Noon Conference

February 2020

Non-alcoholic fatty liver disease (NAFLD) IN 2020, Rotonya M Carr, MD 2/4/20

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.

Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).

Perilipin Staining Distinguishes Between Steatosis and Nonalcoholic Steatohepatitis in Adults and Children.

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.

Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.!/content/playContent/1-s2.0-S0016508510014162?returnurl=null&referrer=null

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus.

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.

Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

Self-reported hypertension treatment beliefs and practices of primary care physicians in a managed care organization.

Nonalcoholic fatty liver disease is underrecognized in the primary care setting.

Long-term follow-up of patients with nonalcoholic fatty liver.!/content/playContent/1-s2.0-S1542356508011191?returnurl=null&referrer=null

Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.!/content/playContent/1-s2.0-S0168827808004236?returnurl=null&referrer=null

The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH.!/content/playContent/1-s2.0-S0016508515008756?returnurl=null&referrer=null

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology.

Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both?

The effects of fatty deposits on the accuracy of the Fibroscan® liver transient elastography ultrasound system.

Liver biopsy.

The utility of radiological imaging in nonalcoholic fatty liver disease.

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.!/content/playContent/1-s2.0-S0016508515004965?returnurl=null&referrer=null

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes.

Statins and hepatic steatosis: perspectives from the Dallas Heart Study.

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.!/content/playContent/1-s2.0-S0016508513008408?returnurl=null&referrer=null

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.

Mechanisms of NAFLD development and therapeutic strategies.

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.!/content/playContent/1-s2.0-S014067361500803X?returnurl=null&referrer=null

Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience.

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus.

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.!/content/playContent/1-s2.0-S0168827816301994?returnurl=null&referrer=null

Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists.

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.

Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study.

A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction in Improving Activity of Non-Alcoholic Fatty Liver Disease.

Glyphosate Excretion is Associated With Steatohepatitis and Advanced Liver Fibrosis in Patients With Fatty Liver Disease.!/content/playContent/1-s2.0-S1542356519303611?returnurl=null&referrer=null

Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

Image Map